-
<![CDATA[Dr Tinajero on the Role of Pharmacists in Treatment Planning and Management in CML]]>
27 Nov 2025 02:46 GMT
… chronic myeloid leukemia (CML).
As treatment has evolved … patients understand drug-food and drug-drug interactions. These … dasatinib (Sprycel), nilotinib (Tasigna), ponatinib (Iclusig), and asciminib … patterns, and concomitant medications. Pharmacists assist …
-
<![CDATA[How Targeted Therapies Are Transforming Chronic Myeloid Leukemia Care ]]>
19 Nov 2025 22:07 GMT
… evolution of chronic myeloid leukemia (CML) treatment, advances in targeted … to one of the newer drugs, Tasigna (nilotinib) or Sprycel (dasatinib … to continue taking the medication.
How does the recent … .
For more news on cancer updates, research and education …
-
<![CDATA[FDA Accepts NDA for New Nilotinib Formulation in Chronic Myeloid Leukemia]]>
22 Oct 2025 21:45 GMT
The US FDA has accepted the new drug application (NDA) … TKI) nilotinib (Tasigna), for treatment of chronic myeloid leukemia (CML).1 … With XS003’s NDA acceptance, a Prescription Drug … before administration, pending FDA review of final labeling …
-
<![CDATA[FDA Accepts NDA for Nilotinib Biosimilar XS003 for Chronic Myeloid Leukemia]]>
21 Oct 2025 21:28 GMT
… (Tasigna), for the treatment of patients with chronic myeloid leukemia … center, randomized phase 1 trial (NCT07138352) designed to … who had an acceptable medical history, physical exam, … /tasigna.pdf
Azurity Pharmaceuticals, Inc. announces FDA approval of …
-
<![CDATA[Pharmacists Play Key Role in Patient Education and Treatment Adherence in CML Management]]>
11 Nov 2025 00:17 GMT
… [Sprycel] and nilotinib [Tasigna], third-generation options like … and often on multiple medications. Pharmacists help screen … in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002 … ;/www.accessdata.fda.gov/drugsatfda_docs/label…
-
<![CDATA[Correlation Observed Between Leukemia Stem Cells and Response in CML]]>
04 Nov 2025 15:26 GMT
… in patients with chronic myeloid leukemia (CML). The findings suggest the … began treatment with imatinib (Gleevec), 30% (n = 72) with nilotinib (Tasigna), and … chronic myeloid leukemia patients: Final results of prospective FLOWERS study. Cancer. 2025 …
-
<![CDATA[October 2025: A Look at FDA Oncology Approvals and Designations]]>
02 Nov 2025 20:03 GMT
… SIDNEY trial (NCT04669171).
On October 21, the FDA accepted the new drug … the TKI nilotinib (Tasigna), for treatment of chronic myeloid leukemia. A PDUFA target … drug designation by the FDA for the treatment of pancreatic cancer.
The FDA granted orphan drug …
-
Novartis' new drugs outweigh Entresto decline in Q3
28 Oct 2025 14:05 GMT
… (secukinumab), plus generic erosion to cancer drug Tasigna (nilotinib) and Promacta/Revolade … .
Narasimhan also highlighted the recent FDA approval of Rhapsido (remibrutinib) in … assets with pipeline-in-a-pill potential that could underpin our …
-
Novartis Q3: new drugs step up as generics squeeze Entresto
28 Oct 2025 15:39 GMT
… medication reduced by 1% in Q3. The drug … platelet disorder treatment Promacta (eltrombopag) and blood cancer drug Tasigna (nilotinib … Avidity Biosciences, a biotech developing RNA therapeutics. … you deserve! The Pharmaceutical Technology Excellence Awards …
-
<![CDATA[FDA Accepts NDA for New Nilotinib Formulation in CML]]>
24 Oct 2025 02:15 GMT
… a treatment for patients with chronic myeloid leukemia … FDA accepts new drug application for XS003 (nilotinib) for the treatment … 45zjp4xs
Tasigna® (nilotinib) Capsules. Prescribing information. FDA. … News release. Azurity Pharmaceuticals, Inc. November 14 …